Semaglutide significantly reduced BMI by up to 18.3% and improved SBP in obese individuals
SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes
Abstract
Semaglutide significantly reduced BMI (up to 18.3%) and improved systolic blood pressure in obese/overweight individuals, indicating potential renal benefits.